ArticleMolecular neurobiology2025
Coenzyme Q10 Modulates BDNF and it is Regulating Non-coding RNAs to Attenuate Motor Deficits and Neurodegeneration in Cerebellum of Cuprizone-Induced Demyelination Rat Model.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Multiple sclerosis (MS) is a progressive neurodegenerative disorder. Limited data exist regarding the molecular mechanisms underlying cerebellar involvement and the potential role of Coenzyme Q10 (CoQ10) in non-coding RNAs in MS. This study aimed to investigate the effects of CoQ10 on histomorphometric changes, motor behaviors, and the expression of BDNF and its regulatory ncRNA in the cerebellar tissue of a rat model of demyelination. The study included four groups: control, Q10 alone, cuprizone-induced demyelination (DM), and DM + Q10 (n = 6 rats/group). Demyelination was induced by administering 0.5% cuprizone mixed in rodent chow for 12 weeks. CoQ10 (200 mg/kg/day) was given by oral gavage, dissolved in 1% sodium carboxymethyl cellulose. Behavioral tests (rotarod, open field, and inverted grid) were conducted to assess motor function. Histological analysis and molecular evaluations were conducted to assess BDNF protein levels and the expression of MALAT1, HOTAIR (HOX Transcript Antisense RNA), and phosphorylated CREB (P-CREB). The results indicated that, compared to the control group, the MS group exhibited reduced motor activity, along with histological alterations in cerebellar Purkinje cells, including decreased cell number and increased pyknosis. Molecular analyses showed a marked upregulation of non-coding RNAs MALAT1 and HOTAIR, alongside significant downregulation in the protein expression levels of BDNF and phosphorylated CREB (P-CREB). Treatment with CoQ10 notably ameliorated these histological changes by improving motor performance, restoring Purkinje cell integrity, reducing the expression of MALAT1 and HOTAIR, and enhancing the levels of BDNF and P-CREB in the cerebellum. Our results indicated that CoQ10, by modulating BDNF signaling and its regulatory non-coding RNAs, effectively counteracted molecular and cellular damage in the cerebellum, improving motor performance. This study provides new insight into the role of CoQ10 in cerebellar protection, an area that has received limited attention in demyelinating disease research.
Indexed as
Identifiers
41206393What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.